Donald Trump's move to cut drug prices in America can potentially turn out to be a $35 billion additional cost to the federal ...
Investor's Business Daily on MSN
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech ...
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback